Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:NTGN

Neon Therapeutics (NTGN) Stock Price, News & Analysis

Neon Therapeutics logo

About Neon Therapeutics Stock (NASDAQ:NTGN)

Key Stats

Today's Range
$3.07
$3.07
50-Day Range
$2.77
$3.07
52-Week Range
$0.88
$6.25
Volume
N/A
Average Volume
516,108 shs
Market Capitalization
$88.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Neon Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Receive NTGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NTGN Stock News Headlines

BCYC Bicycle Therapeutics plc
NTGN_old Historical Data
Blackrock’s Sending THIS Crypto Higher on Purpose
It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…
NBCO Neon Bloom, Inc.
See More Headlines

NTGN Stock Analysis - Frequently Asked Questions

Neon Therapeutics Inc (NASDAQ:NTGN) issued its earnings results on Monday, March, 2nd. The company reported ($0.63) earnings per share for the quarter, beating the consensus estimate of ($0.66) by $0.03.

Neon Therapeutics (NTGN) raised $101 million in an IPO on Wednesday, June 27th 2018. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Morgan Stanley, BofA Merrill Lynch and Mizuho Securities served as the underwriters for the IPO and Oppenheimer was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Neon Therapeutics investors own include VBI Vaccines (VBIV), Vaxart (VXRT), Anavex Life Sciences (AVXL), Occidental Petroleum (OXY), Sorrento Therapeutics (SRNE), Aduro Biotech (ADRO) and Altimmune (ALT).

Company Calendar

Last Earnings
3/02/2020
Today
11/21/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:NTGN
CIK
N/A
Fax
N/A
Employees
102
Year Founded
N/A

Profitability

Net Income
$-79,780,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.50 per share

Miscellaneous

Free Float
N/A
Market Cap
$88.93 million
Optionable
Not Optionable
Beta
-0.81
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:NTGN) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners